Press Release

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25%

As recently announced, initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively; data from the third patient enrolled is expected

Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar

Read More
DEA Blocks MMJ FDA Cannabis Research While Tribal Marijuana Transit Networks Operate in N.C. Unchecked
Press Release

DEA Blocks MMJ FDA Cannabis Research While Tribal Marijuana Transit Networks Operate in N.C. Unchecked

Watch the Senate hearing: https://dai.ly/x9j0le4

Despite MMJ's full regulatory compliance and orphan drug status from the FDA, its DEA manufacturing registration (GROW MARIJUANA) remains stonewalled inside a DEA administrative court system now deemed unconstitutional under Axon and Jarkesy. Meanwhile, tribal transit networks face virtually no enforcement-exposing a hypocritical and dangerous DEA double standard.

Read More